Paper Details

  1. Home
  2. Paper Details

Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease.

Author: MagyarKálmán, RiedererPeter, SzökőÉva, TábiTamás, VécseiLászló

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

MAO-B inhibitors, such as selegiline and rasagiline, have been used to treat Parkinson's disease for over 50 years. These drugs are generally well tolerated and do not cause the side effects associated with non-selective MAO inhibitors. In addition to their MAO-B inhibition activity, selegiline and rasagiline have also been shown to have neuroprotective and antiapoptotic properties.
Paper Details　
Original Abstract of the Article :
The era of MAO-B inhibitors dates back more than 50 years. It began with Kálmán Magyar's outstanding discovery of the selective inhibitor, selegiline. This compound is still regarded as the gold standard of MAO-B inhibition, although newer drugs have also been introduced to the field. It was reveale...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s00702-018-1853-9

データ提供：米国国立医学図書館（NLM）

Neuroprotective Effects of MAO-B Inhibitors: A Pharmacological Review

This study reviews the pharmacological aspects of irreversible MAO-B inhibitors, selegiline and rasagiline, in the treatment of Parkinson's disease. The study highlights the history of MAO-B inhibitors and their role in dopamine sparing, which slows the progression of Parkinson's disease. The study also explores the complex pharmacological profile of selegiline and rasagiline, including their neuroprotective and antiapoptotic properties, which may offer additional benefits beyond dopamine sparing.

Navigating the Desert of Parkinson's Disease: Exploring Neuroprotective Solutions

Parkinson's disease is a challenging condition, like navigating a vast and unforgiving desert. This study explores the potential of MAO-B inhibitors, selegiline and rasagiline, in slowing the progression of this debilitating disease. The study delves into the intricate mechanisms by which these inhibitors work, showcasing their potential to provide a more effective treatment for those living with Parkinson's disease.

A Beacon of Hope in the Desert

This review offers a beacon of hope for those living with Parkinson's disease. The study provides insights into the potential of MAO-B inhibitors to slow the progression of the disease and offers a glimpse into the future of Parkinson's disease treatment.

Dr. Camel's Conclusion

This review provides valuable insights into the pharmacological aspects of irreversible MAO-B inhibitors, selegiline and rasagiline. The study highlights their role in dopamine sparing and their potential neuroprotective and antiapoptotic properties, making them promising therapeutic agents for the treatment of Parkinson's disease.

Date :
  1. Date Completed 2019-11-11
  2. Date Revised 2019-11-11
Further Info :

Pubmed ID

29417334

DOI: Digital Object Identifier

10.1007/s00702-018-1853-9

Related Literature

Article Analysis
・Effects of rasagiline
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.